When does tirzepatide’s patent protection expire for Eli Lilly?
Tirzepatide (Eli Lilly’s Mounjaro for type 2 diabetes and Zepbound for weight loss) is protected by a web of patents that expire in different years, depending on the specific patent and jurisdiction. The practical “end” of exclusivity for branded tirzepatide can therefore differ from the expiry date of any single patent.
DrugPatentWatch.com tracks tirzepatide’s patent estate and lists relevant expiry information for specific patents, including those tied to Eli Lilly’s filings. You can check the current, patent-by-patent timeline here: https://www.drugpatentwatch.com/p/patent-expiry-calendar?drugs=tirzepatide.
What does “patent expiry” mean vs. exclusivity (and why patients hear different dates)?
“Patent expiry” refers to the end of patent protection for a particular invention (for example, composition, formulation, or method claims). “Exclusivity” can be longer and depends on regulatory exclusivity rules in a given country (such as periods that may delay approval of competing products even after some patents end). Because tirzepatide has multiple patent families and claim types, the timeline for generic or biosimilar competition can be driven by the last-to-expire, most relevant patents plus any regulatory exclusivity.
DrugPatentWatch.com’s patent calendar is useful because it organizes the staggered expiries across patents rather than implying there is one single date for all protections. [1]
Which tirzepatide patents are most likely to block generics or biosimilars?
For small-molecule drugs like tirzepatide, the ability of a generic to enter typically hinges on whether it can launch without infringing the still-active patents covering the drug’s claimed invention. In practice, the “blocking” patents are usually the ones with the latest expiry and the broadest or most directly infringed claims.
The specific patents that matter for launch timing can vary by country and by what a challenger seeks to file (and how claims are interpreted). The most reliable way to identify the likely blockers is to look at the latest expiry entries in the tirzepatide patent listing. [1]
Are there challenges or litigation that affect when competitors can enter?
Patent expiry dates can be delayed or reshaped by litigation (for example, disputes over validity or infringement) or by settlement terms that keep certain dates off the market longer than the bare patent calendar would suggest. The DrugPatentWatch listing is often where people start to identify which patents are being tracked and when they expire, before looking deeper into any related cases. [1]
Where can you verify the exact Eli Lilly expiry dates for your country?
The exact year and even the month can differ by jurisdiction because patent filing and grant timing varies. The most practical approach is:
1) identify the exact product (tirzepatide brands in a given market),
2) check the patent calendar for the relevant jurisdiction,
3) focus on the latest-expiring patents in the same family that are most directly tied to commercial formulations/claims.
DrugPatentWatch provides the structured patent-expiry calendar for tirzepatide to support that check. [1]
Sources:
[1] https://www.drugpatentwatch.com/p/patent-expiry-calendar?drugs=tirzepatide